3 Strong Buy stocks with 100% upside potential

Every stock investor wants a high return; it’s axiomatic, which is why people go public to begin with. But markets are inherently risky, and finding the sweet spot – the right mix of risk and reward – seems as much an art as a science. You can however use science to minimize the risk. We are talking about statistical science, the study of numbers, their patterns and the relationships between them. This can give investors an objective view of the larger market or specific stocks, and can even be used to measure the success of these stock performers, professional traders and analysts. We used the tools on the TipRanks platform to sort publicly traded stocks and find three that have a strong combination of risk and reward. Specifically, we looked for Strong Buy stocks that have recently received analyst approval, as well as a price target suggesting upside potential of 100% or more. Doubling your money seems like a good return, so let’s find out what else these stocks have for them. Rezolute (RZLT) We’ll start with the biopharmaceutical industry, where Rezolute specializes in the development of drug therapies – new drugs – for patients with difficult-to-treat metabolic disorders. These are often seen as orphan diseases, diseases that have very few patients and therefore a limited market. Rezolute is currently working on two pipeline projects, both for conditions similar to or related to diabetes. The Company’s lead drug candidate, RZ358, is currently in an open label Phase 2b study as a treatment for congenital hyperinsulinism (CHI), a rare pediatric disease in which the pancreas produces too much insulin , resulting in extremely low blood sugar, with cascading effects throughout the body. RZ402, the second drug candidate, is in phase 1 clinical trials. This is an oral treatment for diabetic macular edema, one of the causes of blindness in diabetes. In its recent financial report for the third quarter of fiscal 2021, Rezolute included updates on the development of the two main drug candidates. For RZ358, the company noted that the phase 2b RIZE study was still enrolling patients and that baseline data should be available during 2H21. For the Phase 1 study of RZ402, Resolute announced that the trial has ended and initial results show that oral administration once daily is feasible. The company will launch a Phase 1b trial in 3Q21, as a step towards Phase 2 studies. Regarding the financial results, Rezolute said it has on hand $ 32 million available in cash and cash equivalents, enough to fund. operations through the third calendar quarter of 2022. HC Wainwright five-star analyst Douglas Tsao began his coverage of RZLT with an optimistic outlook, writing: “Rezolute is set to step into the limelight with two assets to the mechanisms Unprecedented… Despite assets with promising data and differentiated mechanisms, Rezolute has been largely overlooked by the investment community, which we largely attribute to its entry into the public markets via a reverse merger and an OTC List. keys ahead and a recent NASDAQ listing, we think it’s time for investors to pay attention to this story. Tsao is giving the stock a no. te purchase and a target price of $ 21, which implies an increase of 103% for the coming year. (To see Tsao’s review, click here.) The Strong Buy consensus rating on RZLT shares is based on 3 recent reviews – and they are all positive, unanimously agreed by consensus. The shares are priced at $ 10.33, with an average price target of $ 25.33, making the one-year upside potential a solid 145%. (See Rezolute’s market analysis on TipRanks.) Westport Fuel Systems, Inc. (WPRT) Next, we have Westport Fuel Systems, a company that operates in the green sector of the energy and transportation industry, producing natural gas engines and associated fuel system components, for personal and commercial vehicles. Westport is a leader in high pressure direct injection technology and also produces engines designed for propane or hydrogen fuels. Westport holds 1,400 patents or patent applications relating to alternative fuel systems. Last year, the company achieved sales in 70 countries, with total revenue of $ 252 million. In the current year’s first quarter report, Westport reported revenue of $ 76.4 million, beating estimates of $ 3.81 million and up 14% from 1Q20, putting the company on track to beat last year’s total. The company recorded a net loss in the first quarter; however, despite the lack of $ 0.01 from the street forecast, the loss of 2 cents per share was well below the loss of 12 cents recorded in the last year’s quarter. Westport has a stated goal of reaching $ 1 billion in annual business by the middle of this decade. Amit Dayal, 5-star analyst at HC Wainwright, covers this headline, and he was impressed with the first quarter results. Dayal wrote: “The strength in year-over-year revenues is attributed to a 25.0% increase in OEM sales supported by demand for light vehicles. Gross margins for the quarter improved to 17.0% from 15.5% in 4Q20, supported by the product mix. Regarding the outlook for the company, the analyst added, “A key takeaway from the call was management’s increasing focus on growth in North America. We believe regulators in this geography are now pressuring fleet owners to look for cleaner trucks. This, in our opinion, plays on the company’s available solutions that already meet this need. Consistent with these comments, Dayal rated the WPRT shares as a buy. Its price target, at $ 16, indicates confidence in a 155% rise for the 12-month nest. (To view Dayal’s track record, click here.) Like RZLT above, Westport received 3 positive stock reviews for a unanimous Strong Buy consensus rating. WPRT shares have an average price target of $ 13.33, which implies a one-year increase of 112% from the current price of $ 6.26. (See Westport stock market analysis on TipRanks.) Ayr Wellness (AYRWF) For the last headline on our list, we’ll look to the fast-growing cannabis industry. Ayr Wellness is a United States-based cannabis company, an MSO (multi-state operator) with operations ranging from growing the plants to distributing the product. Ayr has dispensaries in Arizona, Florida, Massachusetts, Nevada and Pennsylvania, and offers a range of products for medicinal and recreational users. The legal cannabis market is young and continues to grow rapidly. In Ayr’s 1Q21 report, the company showed a 74% year-over-year gain to $ 58.4 million. Ayr focused on expanding his footprint. During the quarter, he completed the acquisition of Liberty Health Sciences in Florida. The move added 42 dispensaries to Ayr’s Florida operation, giving the company the fourth-largest “ cannabis footprint ” in the third-largest state. Ayr also made acquisitions in Arizona and Ohio, with Ohio operations scheduled to begin in the next quarter. The company plans to enter the New Jersey market by the end of the summer. Echelon analyst Andrew Semple sees the company’s expansion as the driving force here, and he writes of Ayr: “We expect strong growth to come with our forecast for sales to exceed 120. million by Q420, more than double Q1 levels. In the coming quarters, Ayr will benefit from the full first quarter of the contribution of its operations acquired in Arizona and Florida, the closing of the acquisition of Garden State Dispensary in New Jersey (expected in Q321), significant increases in capacity in Arizona, Pennsylvania, Florida, New Jersey, and Nevada (as well as MA / OH due to go live in 2022), and 14 new dispensaries operational by YE 2021 compared to QE Q121. Semple, a 5-star analyst ranked among Wall Street’s Top 100 Analysts, gives stocks a buy rating and raises his price target from C $ 70 ($ 58) to C $ 74 ($ 61), suggesting a 100% increase for the coming year. . (To see Semple’s track record, click here.) There are 5 recent reviews on this stock, with a 4: 1 split in favor of buy over hold, all merging into a Strong consensus rating. Buy. The average price target is $ 45.58, which implies a 49% hike in the coming year. (See Ayr Wellness stock market analysis on TipRanks. To find great ideas for trading stocks at attractive valuations, visit Top Stocks to Buy from TipRanks, a newly launched tool that brings together all the information about stocks from TipRanks Disclaimer: The opinions expressed in this article are solely those of featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

About The Author

Related Posts

Leave a Reply

Your email address will not be published.